Cyclophosphamide Attenuates Fibrosis in Lupus Nephritis by Regulating Mesangial Cell Cycle Progression

• Published in: Disease markers Vol. 2021; pp. 1 - 9
• Main Authors: Ma, Yuehong, Fang, Ling, Zhang, Rui, Zhao, Peng, Li, Yafeng, Li, Rongshan
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2021; John Wiley & Sons, Inc
• Subjects: Actin; Animal tissues; Animals; Apoptosis; Biotechnology; Cell cycle; Cell Cycle Checkpoints; Cell growth; Cell Proliferation; Cells, Cultured; Chronic conditions; Cyclin-dependent kinase; Cyclin-dependent kinase inhibitors; Cyclins; Cyclophosphamide; Cyclophosphamide - pharmacology; Disease; Female; Fibrosis; Fibrosis - drug therapy; Fibrosis - etiology; Fibrosis - pathology; Flow cytometry; G1 phase; Gene expression; Growth factors; Histopathology; IL-1β; Immunosuppressive Agents - pharmacology; Inflammation; Interleukins; Kidneys; Kinases; Laboratory animals; Lupus; Lupus nephritis; Lupus Nephritis - complications; Mesangial cells; Mesangial Cells - drug effects; Mesangial Cells - metabolism; Mesangial Cells - pathology; Mice; Mice, Inbred C57BL; mRNA; Muscles; Nephritis; Platelet-derived growth factor; Smooth muscle; Systemic lupus erythematosus; United States > US; China
• ISSN: 0278-0240; 1875-8630; 1875-8630
• DOI: 10.1155/2021/3803601

Objectives. Most patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) with severe kidney manifestations. Renal fibrosis can be primarily attributed to overproliferation of mesangial cells (MCs), which are subject to drug treatment. Nevertheless, the detailed mechanisms remain elusive. We sought to identify the effect of cyclophosphamide (CTX), a drug commonly used for LN treatment, on MC proliferation and explore its underlying mechanisms. Material/Methods. Cell proliferation and fibrosis in mouse kidney tissues were determined by histopathology staining techniques. Flow cytometry was used for cell cycle analysis. Cell cycle regulators were examined in vitro following treatment of immortalized human MCs with platelet-derived growth factor subunit B (PDGF-B). Quantitative real-time PCR and western blot analyses were used to measure the mRNA and protein levels of candidate cell cycle regulators, respectively. Results. CTX inhibited cell overproliferation induced by platelet-derived growth factor subunit B in vitro and in vivo. CTX (40 mg/l) was sufficient to induce G0/G1 phase cell cycle arrest. CTX treatment downregulated many critical cell cycle regulators including cyclins and cyclin-dependent kinases but upregulated cyclin-dependent kinase inhibitors. Additionally, CTX-treated samples showed significantly reduced fibrosis, as indicated by lower expression of interleukin-1β and α-smooth muscle actin. Conclusion. CTX inhibits proliferation of MCs by modulating cell cycle regulator and therefore arresting them at G1 phase. CTX treatment significantly alleviates the severity of renal fibrosis. These findings provide novel insights into the mechanisms by which CTX affects LN.